Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 30:ehaf679.
doi: 10.1093/eurheartj/ehaf679. Online ahead of print.

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

Manan Pareek  1   2 , Mats C Højbjerg Lassen  1   2 , Niklas Dyrby Johansen  1   2 , Sine H Christensen  1   2 , Negar Aliabadi  3 , Kristoffer G Skaarup  1   2 , Daniel Modin  1   2 , Brian L Claggett  4 , Carsten S Larsen  5   6 , Lykke Larsen  7 , Lothar Wiese  8 , Michael Dalager-Pedersen  9   10 , Matias G Lindholm  11 , Anne Marie R Jensen  1   2 , Maria Dons  1   2 , Katrine F Bernholm  1   2 , Filip S Davidovski  1   2 , Lisa S Duus  1   2 , Camilla I Ottosen  1   2 , Anne B Nielsen  1   2 , Julie H Borchsenius  1   2 , Caroline Espersen  1   2 , Güldas Köse  1   2 , Frederik H Fussing  1   2 , Lars Køber  12   13 , Scott D Solomon  4 , Jens Ulrik Stæhr Jensen  12   14 , Cyril Jean-Marie Martel  15 , Bradford D Gessner  3 , Claudia Schwarz  3 , Elisa Gonzalez  3 , Mette Skovdal  3 , Pingping Zhang  3 , Elizabeth Begier  3 , Tor Biering-Sørensen  1   2   13   16
Affiliations

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

Manan Pareek et al. Eur Heart J. .

Abstract

Background and aims: It is not known whether the bivalent respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine reduces outcomes in individuals with atherosclerotic cardiovascular disease (ASCVD). The aim was to evaluate the vaccine effectiveness (VE) of an RSVpreF vaccine vs no vaccine on respiratory and cardiovascular outcomes in persons with or without pre-existing ASCVD.

Methods: We conducted a prespecified secondary analysis of the DAN-RSV trial. Adults aged ≥60 years were randomized 1:1 to RSVpreF vaccine or no vaccine. Baseline and outcome data were collected through nationwide registries. The primary outcome was respiratory syncytial virus-related respiratory tract disease hospitalization. The principal major adverse cardiovascular event outcome was a composite of hospitalization for myocardial infarction, stroke, or heart failure. Heterogeneity in VE was assessed among participants with and without ASCVD.

Results: The incidence rate of almost all outcomes was higher in participants with pre-existing ASCVD (n = 14 241) vs those without (n = 117 035). Vaccine effectiveness was generally consistent by ASCVD status (Pinteraction ≥ .05 for all but one interaction). Among persons without and with ASCVD, VE for the primary outcome was 80.0% [95% confidence interval (CI), 29.3-96.3] vs 100.0% (95% CI, -141.3 to 100.0), respectively (Pinteraction > .99). Vaccine effectiveness for major adverse cardiovascular events was 9.3% (95% CI, -15.1 to 28.6) in participants without, and 12.0% (95% CI, -34.6 to 43.3) in participants with, pre-existing ASCVD (Pinteraction = .90).

Conclusions: The VE of an RSVpreF vaccine vs no vaccine against respiratory and cardiovascular outcomes was similar among individuals ≥ 60 years of age with pre-existing ASCVD as compared with those without.

Keywords: Atherosclerosis; Cardiovascular diseases; Randomized controlled trial; Registries; Respiratory syncytial virus; Vaccination.

PubMed Disclaimer

Grants and funding